Patent granted for MS drug Tecfidera (BG-12) until 2028
Posted: Wed Mar 20, 2013 1:08 am
Patent granted for Multiple Sclerosis drug Tecfidera (BG-12) until 2028
Biogen Idec Inc announces it has been granted a new patent that will help protect the market exclusivity of its multiple sclerosis drug Tecfidera (BG-12) until 2028.
The new patent covers the dosing regimen for Tecfidera of 480 milligrams a day....Read more - http://www.ms-uk.org/index.cfm/BG12
Biogen Idec Inc announces it has been granted a new patent that will help protect the market exclusivity of its multiple sclerosis drug Tecfidera (BG-12) until 2028.
The new patent covers the dosing regimen for Tecfidera of 480 milligrams a day....Read more - http://www.ms-uk.org/index.cfm/BG12